Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT06951399 by Rabin Medical Center, with a registry enrolment figure of 30 participants, started 2025-09-01 and due to reach its primary completion in 2027-08-30. Interventions recorded: Pembrolizumab (KEYTRUDA®). Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC Stage IV Without EGFR/ALK Mutation; NSCLC Adenocarcinoma. Primary outcome: Change in T-cell Receptor (TCR) Repertoire Clonality and Diversity Relative to Disease Response Assessed by RECIST v1.1. Lung eligibility wording from the registry: "* Histologically confirmed diagnosis of NSCLC adenocarcinoma stage IV or unresectable stage III". Sites: Israel. No results are recorded here; the registry entry is the source.